Filing Flows

Filing Flows › 8-K events › PTC Therapeutics

PTC Therapeutics: results of operations

Form 8-K filed Oct 29, 2026 · items 2.02, 7.01

Results of operationsPTC Therapeutics Provides Corporate Update

What the filing says

– Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue – – Full-year 2026 expected total revenue increased to $1.29 to $1.32 billion, with full-year product revenue guidance raised to $960 to $990 million –

ScaleThe filing names $1.32B: about 92% of PTC Therapeutics' annual revenue ($1.43B, four times the latest quarter).

Read the filing on SEC EDGAR →

What usually followsAcross 69,115 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Every item ranked →

PTC Therapeutics at a glance

Latest quarterQ3 2026
Revenue$357.8M
Revenue Y/Y+70%
Operating margin7.0%
IndustryPharmaceutical Preparations

PTC Therapeutics, Q3 2026: revenue $358M (+70% year over year), operating margin 7.0%. The chart follows the revenue to costs, profit and cash.

PTC Therapeutics: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent guidance

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.